- Home
- LANC vs OCEAW Comparison
LANC vs OCEAW Comparison
Compare LANC & OCEAW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LANC
- OCEAW
- Stock Information
- Founded
- LANC 1961
- OCEAW N/A
- Country
- LANC United States
- OCEAW United States
- Employees
- LANC N/A
- OCEAW 7
- Industry
- LANC Packaged Foods
- OCEAW Biotechnology: Pharmaceutical Preparations
- Sector
- LANC Consumer Staples
- OCEAW Health Care
- Exchange
- LANC Nasdaq
- OCEAW Nasdaq
- Market Cap
- LANC N/A
- OCEAW N/A
- IPO Year
- LANC N/A
- OCEAW 2021
- Fundamental
- Price
- LANC $190.33
- OCEAW $0.02
- Analyst Decision
- LANC Buy
- OCEAW
- Analyst Count
- LANC 4
- OCEAW 0
- Target Price
- LANC $211.33
- OCEAW N/A
- AVG Volume (30 Days)
- LANC 170.7K
- OCEAW N/A
- Earning Date
- LANC 04-30-2025
- OCEAW N/A
- Dividend Yield
- LANC 1.99%
- OCEAW N/A
- EPS Growth
- LANC 21.25
- OCEAW N/A
- EPS
- LANC 5.69
- OCEAW N/A
- Revenue
- LANC $1,900,130,000.00
- OCEAW N/A
- Revenue This Year
- LANC $5.03
- OCEAW N/A
- Revenue Next Year
- LANC $3.31
- OCEAW N/A
- P/E Ratio
- LANC $33.60
- OCEAW N/A
- Revenue Growth
- LANC 1.77
- OCEAW N/A
- 52 Week Low
- LANC $163.20
- OCEAW N/A
- 52 Week High
- LANC $202.63
- OCEAW N/A
- Technical
- Relative Strength Index (RSI)
- LANC 61.99
- OCEAW N/A
- Support Level
- LANC $181.55
- OCEAW N/A
- Resistance Level
- LANC $193.40
- OCEAW N/A
- Average True Range (ATR)
- LANC 5.80
- OCEAW 0.00
- MACD
- LANC 1.51
- OCEAW 0.00
- Stochastic Oscillator
- LANC 86.29
- OCEAW 0.00
About OCEAW Ocean Biomediacal Inc.
Ocean Biomedical Inc is a biopharmaceutical company that is focused on discovering and developing therapeutic products in oncology, fibrosis, and infectious diseases. The company is developing an antibody therapeutic product candidate inhibiting Chi3l1, and a bi-specific antibody product candidate inhibiting Chi3l1 plus PD-1 and CTLA-4 for the treatment of non-small cell lung cancer and glioblastoma multiforme; and a small molecule product candidate targeting Chit1 for the treatment of Idiopathic Pulmonary Fibrosis and Hermansky-Pudlak Syndrome.